Ozempic Is Transforming the Global Food Market: Why Weight-Loss Drugs Have Become a Threat to PepsiCo, Snack Manufacturers, and Fast-Food Chains
Weight-loss drugs like Ozempic, Wegovy, and Mounjaro are impacting the food industry, with U.S. households using these drugs cutting grocery spending by 5.3% and fast-food spending by 8%. PepsiCo, among other food giants, is adjusting its strategies as snack and sweet sales decline. PepsiCo reported a 2% drop in North American beverage sales and lowered its 2026 earnings forecast to 1–2% growth, down from 4–6%.
How this was made
The 30-second read
Why it matters
PepsiCo's guidance downgrade is the most concrete market‑moving element; the broader consumer‑food trend adds a longer‑term sector risk.
Market read
Guidance cut is a primary catalyst for immediate price action; sector‑wide appetite‑suppression could affect peers.
What to watch
The company may benefit from higher‑margin protein and ready‑to‑eat segments as consumer preferences shift.
Background
The article discusses how GLP‑1 weight‑loss drugs like Ozempic are reducing snack and fast‑food spending, and ties this trend to PepsiCo's recent earnings release and guidance cut.
Ticker impact
PepsiCo lowered its 2026 core EPS growth guidance to 1‑2% from 4‑6% in its October 8 quarterly release.
downward pressure as investors price in lower earnings growth
Guidance revisions are a primary catalyst for price moves; the cut is material for a large‑cap consumer staple.
Market effects
Weight‑loss drugs may erode snack demand, pressuring broader consumer‑staples and food‑beverage sector.
U.S. consumer spending on snacks and fast food could decline, affecting domestic retailers.
If GLP‑1 adoption expands, similar effects may appear in other markets, reshaping global food‑product demand.
Counterpoint
PepsiCo's price cuts and product innovation could mitigate demand loss, offering a buying opportunity at lower valuations.
Key entities
- companyPepsiCo
Global food and beverage giant facing reduced snack demand.
